379 related articles for article (PubMed ID: 38158454)
21. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
22. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
23. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Buchbinder EI; Desai A
Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in the Treatment of Cancer.
Zam W; Ali L
Curr Rev Clin Exp Pharmacol; 2022; 17(2):103-113. PubMed ID: 33823768
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.
Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Abolghasemi H; Ghaffari SH; Momeny M; Bashash D
Eur J Pharmacol; 2021 Oct; 909():174404. PubMed ID: 34363829
[TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
27. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
28. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
29. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
31. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
32. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
33. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
[TBL] [Abstract][Full Text] [Related]
34. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Horn L; Reck M; Spigel DR
Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
[TBL] [Abstract][Full Text] [Related]
35. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Azoury SC; Straughan DM; Shukla V
Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
[TBL] [Abstract][Full Text] [Related]
37. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
39. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
40. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]